On May 7, 2020 Strata Oncology, a precision oncology company advancing molecular indications for cancer therapies, reported three studies highlighting data featuring its comprehensive genomic profiling (CGP) assay StrataNGSTM will be presented at the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), taking place digitally from May 29 – May 31 (Press release, Strata Oncology, MAY 7, 2020, View Source [SID1234557400]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
All abstracts are available online May 13.
Abstract # 3574, "PCR-based Comprehensive Genomic Profiling: Feasibility From >20,000 Tumor Tissues Specimens and Predicted Impact on Actionable Biomarker Identification Versus Hybrid Capture and Plasma" presented by Scott Tomlins, M.D., Ph.D., Strata Oncology
Abstract # 312647, "The Impact of Tumor NGS Testing on Hereditary Cancer Risk Assessment and Population Management in an Integrated Community Health Care System" presented by Sachdev Thomas, M.D., Kaiser Permanente Northern California
Abstract # e19185, "Implementing a Genomic Oncology Program in an Integrated Health Care Network with Large Scale Genomic Next Generation Sequencing (NGS) Testing of Advanced Cancers in a Community Setting" presented by Marie Suga, M.D., Kaiser Permanente Northern California
About StrataNGS
StrataNGS is a comprehensive genomic profiling assay that assesses DNA and RNA in solid tumors. The assay requires industry-low tumor tissue requirements (0.5mm2). StrataNGS is performed on co-isolated RNA and DNA and detects all classes of genomic alterations, including SNVs, small insertions and deletions, gene fusions, exon skipping mutations and copy number changes. Results include MSI and TMB to help inform immunotherapy decisions.